MX2016004239A - Anticuerpos anti-epcam y métodos de uso. - Google Patents
Anticuerpos anti-epcam y métodos de uso.Info
- Publication number
- MX2016004239A MX2016004239A MX2016004239A MX2016004239A MX2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A MX 2016004239 A MX2016004239 A MX 2016004239A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- scfv
- fab
- combination
- effector molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion se refiere a composiciones de anticuerpos e inmunoconjugados que potencialmente carecen de epítopes de células T y provocan una respuesta inmunitaria reducida. El anticuerpo puede ser un fragmento de anticuerpo, tales como Fab, Fab´, F(ab´)2, scFv, dsFv, ds-scFv, dímeros, minicuerpos, diacuerpos, fragmentos de anticuerpo biespecíficos, multímeros, y cualquier combinación de los mismos. En una modalidad adicional, el anticuerpo puede unir a una molécula de adhesión de celulas epiteliales de antigeno (EpCAM). En otra modalidad, un inmunoconjugado puede comprender un anticuerpo unido a una molécula efectora, en donde la molécula efectora puede ser un radioisótopo, un agente antineoplásico, un inmunomodulador, un modificador de la respuesta biológica, lectina, una toxina, un cromóforo, un fluoróforo, un compuesto quimioluminiscente, una enzima, un ion de metal, y cualquier combinación de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361885817P | 2013-10-02 | 2013-10-02 | |
US201462030805P | 2014-07-30 | 2014-07-30 | |
PCT/CA2014/050950 WO2015048901A1 (en) | 2013-10-02 | 2014-10-02 | Anti-epcam antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016004239A true MX2016004239A (es) | 2016-11-14 |
Family
ID=52778265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004239A MX2016004239A (es) | 2013-10-02 | 2014-10-02 | Anticuerpos anti-epcam y métodos de uso. |
Country Status (18)
Country | Link |
---|---|
US (1) | US9822182B2 (es) |
EP (1) | EP3052525B1 (es) |
JP (1) | JP2017504621A (es) |
KR (1) | KR20160058954A (es) |
CN (1) | CN105764925A (es) |
AU (1) | AU2014331494A1 (es) |
BR (1) | BR112016007232A2 (es) |
CA (1) | CA2925915C (es) |
DK (1) | DK3052525T3 (es) |
ES (1) | ES2747273T3 (es) |
HU (1) | HUE046673T2 (es) |
IL (1) | IL244590A0 (es) |
MX (1) | MX2016004239A (es) |
PL (1) | PL3052525T3 (es) |
PT (1) | PT3052525T (es) |
RU (1) | RU2016116549A (es) |
SG (1) | SG11201602170XA (es) |
WO (1) | WO2015048901A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE033533T2 (en) | 2003-04-30 | 2017-12-28 | Universität Zuerich | A method of treating cancer using immunotoxin |
WO2015048901A1 (en) | 2013-10-02 | 2015-04-09 | Viventia Bio Inc. | Anti-epcam antibodies and methods of use |
US10583198B2 (en) | 2015-03-12 | 2020-03-10 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
CN108513547A (zh) | 2015-03-12 | 2018-09-07 | 维文蒂亚生物公司 | 用于epcam阳性膀胱癌的治疗方法 |
EP3328897A1 (en) | 2015-07-31 | 2018-06-06 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES |
CA3031846A1 (en) | 2016-07-26 | 2018-02-01 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
JP7387196B2 (ja) | 2019-06-11 | 2023-11-28 | バイオアトラ インコーポレイテッド | 条件付きで活性な抗epcam抗体、抗体フラグメント、それらのイムノコンジュゲート、及びそれらの使用 |
CN110950959B (zh) * | 2020-02-25 | 2020-07-03 | 和铂医药(上海)有限责任公司 | 靶向EpCAM的抗体及其制备和应用 |
WO2023195852A1 (en) | 2022-04-06 | 2023-10-12 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Epithelial cell adhesion molecule (epcam)-fluorescence imaging molecule for the detection of gastrointestinal tumors and cancer positive lymph nodes |
CN116875520A (zh) * | 2023-07-12 | 2023-10-13 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
US20030148463A1 (en) * | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
WO1998055623A1 (en) | 1997-06-06 | 1998-12-10 | Tanox Pharma B.V. | Type-1 ribosome-inactivating protein |
DK1037927T3 (da) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
US6280742B1 (en) | 1998-06-17 | 2001-08-28 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
ES2308981T3 (es) | 1999-04-09 | 2008-12-16 | Universitat Zurich | Metodo para la estabilizacion de las inmunoglobulinas hibridas o fragmentos de inmunoglobulina y fragmentos anti-egp-2-scfv estabilizado. |
GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
CA2446087C (en) | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
US20030148950A1 (en) | 2001-10-09 | 2003-08-07 | Li Xin | Kringle domain 1 of human hepatocyte growth factor and uses therefor |
KR20050036875A (ko) | 2001-10-15 | 2005-04-20 | 이뮤노메딕스, 인코오포레이티드 | 직접 표적형의 결합 단백질 |
US20040022726A1 (en) | 2002-06-03 | 2004-02-05 | Goldenberg David M. | Methods and compositions for intravesical therapy of bladder cancer |
SI21272A (sl) | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli |
CA2424255A1 (en) | 2003-03-26 | 2004-09-26 | Claudio Di Paolo | Immunotoxins |
HUE033533T2 (en) | 2003-04-30 | 2017-12-28 | Universität Zuerich | A method of treating cancer using immunotoxin |
PT1737961E (pt) | 2004-03-19 | 2013-08-26 | Merck Patent Gmbh | Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas |
CN1954073B (zh) * | 2004-03-19 | 2013-01-16 | 默克专利股份有限公司 | 被修饰Bouganin蛋白、细胞毒素及其方法和用途 |
CA2569788C (en) | 2004-06-10 | 2014-03-18 | Viventia Biotech Inc. | Tumor specific antibody |
NZ556055A (en) * | 2004-12-21 | 2009-12-24 | Viventia Biotech Inc | Cancer specific antibody and cell surface proteins |
US20090171317A1 (en) | 2006-03-10 | 2009-07-02 | Ebrahim Versi | Self-Catheterization Device To Administes Compounds To The Bladder |
CA2668017A1 (en) | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Improved conjugates |
US8263744B2 (en) * | 2007-04-19 | 2012-09-11 | Viventia Biotechnologies Inc. | Binding proteins that bind to EpCAM linked to an effector molecule |
CA2700815A1 (en) | 2007-09-27 | 2009-04-02 | Viventia Biotech Inc. | Optimized nucleic acid sequences for the expression of vb4-845 |
CA2618163A1 (en) | 2008-02-07 | 2009-08-07 | K. W. Michael Siu | Head and neck cancer biomarkers |
US20110171219A1 (en) * | 2008-09-19 | 2011-07-14 | Fahar Merchant | Treating cancer stem cells using targeted cargo proteins |
KR20110140124A (ko) | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | 암치료용 아미톡신-활성 표적 결합 부위 |
GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
CN107080847A (zh) | 2011-06-24 | 2017-08-22 | 森彻斯有限公司 | 细胞外靶向药物缀合物 |
KR20160006697A (ko) | 2013-04-12 | 2016-01-19 | 비벤티아 바이오 인코포레이티드 | 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법 |
WO2015048901A1 (en) | 2013-10-02 | 2015-04-09 | Viventia Bio Inc. | Anti-epcam antibodies and methods of use |
US10583198B2 (en) | 2015-03-12 | 2020-03-10 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
WO2017040801A2 (en) | 2015-09-02 | 2017-03-09 | Viventia Bio Inc. | Methods for making and using an immunoconjugate for the treatment of cancer |
-
2014
- 2014-10-02 WO PCT/CA2014/050950 patent/WO2015048901A1/en active Application Filing
- 2014-10-02 SG SG11201602170XA patent/SG11201602170XA/en unknown
- 2014-10-02 RU RU2016116549A patent/RU2016116549A/ru not_active Application Discontinuation
- 2014-10-02 ES ES14850812T patent/ES2747273T3/es active Active
- 2014-10-02 CN CN201480064476.XA patent/CN105764925A/zh active Pending
- 2014-10-02 JP JP2016546127A patent/JP2017504621A/ja not_active Withdrawn
- 2014-10-02 BR BR112016007232A patent/BR112016007232A2/pt active Search and Examination
- 2014-10-02 DK DK14850812.0T patent/DK3052525T3/da active
- 2014-10-02 EP EP14850812.0A patent/EP3052525B1/en active Active
- 2014-10-02 CA CA2925915A patent/CA2925915C/en active Active
- 2014-10-02 US US15/026,834 patent/US9822182B2/en active Active
- 2014-10-02 AU AU2014331494A patent/AU2014331494A1/en not_active Abandoned
- 2014-10-02 HU HUE14850812A patent/HUE046673T2/hu unknown
- 2014-10-02 KR KR1020167011071A patent/KR20160058954A/ko not_active Application Discontinuation
- 2014-10-02 MX MX2016004239A patent/MX2016004239A/es unknown
- 2014-10-02 PT PT148508120T patent/PT3052525T/pt unknown
- 2014-10-02 PL PL14850812T patent/PL3052525T3/pl unknown
-
2016
- 2016-03-14 IL IL244590A patent/IL244590A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017504621A (ja) | 2017-02-09 |
AU2014331494A1 (en) | 2016-04-07 |
BR112016007232A2 (pt) | 2018-01-23 |
US20160237164A1 (en) | 2016-08-18 |
RU2016116549A (ru) | 2017-11-09 |
WO2015048901A1 (en) | 2015-04-09 |
IL244590A0 (en) | 2016-04-21 |
US9822182B2 (en) | 2017-11-21 |
CA2925915A1 (en) | 2015-04-09 |
PT3052525T (pt) | 2019-10-18 |
EP3052525A4 (en) | 2017-03-29 |
DK3052525T3 (da) | 2019-10-07 |
HUE046673T2 (hu) | 2020-03-30 |
CA2925915C (en) | 2023-05-02 |
CN105764925A (zh) | 2016-07-13 |
PL3052525T3 (pl) | 2020-03-31 |
EP3052525B1 (en) | 2019-07-24 |
KR20160058954A (ko) | 2016-05-25 |
EP3052525A1 (en) | 2016-08-10 |
ES2747273T3 (es) | 2020-03-10 |
SG11201602170XA (en) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016004239A (es) | Anticuerpos anti-epcam y métodos de uso. | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
MX356947B (es) | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. | |
EA201891040A1 (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
CL2011003148A1 (es) | Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso. | |
BR112016000666A2 (pt) | Constructos de ligação de antígeno cd3 e cd19 biespecíficos | |
PH12020551970A1 (en) | Anti-muc1 antibody | |
WO2013054331A8 (en) | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) | |
NZ720765A (en) | Antibodies and methods of use | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
BR112014005644A2 (pt) | anticorpo anti-alfabetatcr | |
EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
EA201990673A1 (ru) | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты | |
WO2011085165A3 (en) | Ca-125 immune complexes as biomarkers of ovarian cancer | |
EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
PH12015501632A1 (en) | Humanized anti-hmgbi antibody or antigen-binding fragment thereof | |
EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
ZA202008095B (en) | Humanized antibodies against psma | |
EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
WO2014145961A3 (en) | Hybridoma clones and monoclonal antibodies to tetraspanin 8 | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
RU2017124512A (ru) | Способ определения антител, вызывающих комплемент-зависимую цитотоксичность | |
WO2014145940A3 (en) | Hybridoma clones and monoclonal antibodies to cd9 |